NEW YORK – M2Gen said Wednesday that it has received an unspecified new investment from Clayton, Dubilier & Rice, the Merck Global Health Innovation Fund, and McKesson Ventures. M2Gen said that the investment makes private equity firm CD&R its largest shareholder.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.